[Results of treatment with recombinant human growth hormone in children with growth retardation in end-stage renal disease].
The aim of the study was to estimate the results of recombinant human growth hormone (rhGH) treatment in children with end-stage renal disease (ESRD). 60 growth retarded children with ESRD (mean age 11.2 +/- 7.2 years) were treated with rhGH at a dose of 1-1.1 IU/kg/week. The time of observation was 24 months. Thirty children completed first year, 18--second year of treatment. The mean growth velocity prior to the treatment was 3.03 +/- 1.9, during first year of the study--7.52 +/- 2.42, during second year 6.68 +/- 2.87 cm/year. The negative correlation between growth velocity and patient's age (r = -0.39; p < 0.05) suggest the better growth results in younger children during rhGH treatment. The rhGH therapy is effective method of treatment in growth retarded children with ESRD. Side effects are rare.
Sieniawska
M
M
Katedra i Klinika Pediatrii i Nefrologii Akademii Medycznej w Warszawie.
Pańczyk-Tomaszewska
M
M
Ziółkowska
H
H
Jedrzejowski
A
A
Leszczyńska
B
B
Dyras
P
P
Kałuzyńska
A
A
Makulska
I
I
Pietrzyk
J A
JA
Rubik
J
J
Siteń
G
G
Stachowski
J
J
Szprynger
K
K
Zurowska
A
A
Roszkowska-Blaim
M
M
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000150:complications* / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D016896:Treatment Outcome
D019382:Human Growth Hormone